Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA 11,030
-180 (-1.61%)
Aug 28, 2026, 1:48 PM IDT
TLV:TEVA Revenue
Teva Pharmaceutical Industries had revenue of $4.14B USD in the quarter ending June 30, 2026, a decrease of -0.81%. This brings the company's revenue in the last twelve months to $17.32B, up 4.13% year-over-year. In the year 2025, Teva Pharmaceutical Industries had annual revenue of $17.26B with 4.32% growth.
Revenue (ttm)
$17.32B
Revenue Growth
+4.13%
P/S Ratio
2.52
Revenue / Employee
$527.22K
Employees
32,842
Market Cap
129.98B ILS
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.26B | 714.00M | 4.32% |
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
| Dec 31, 2018 | 18.27B | -3.58B | -16.39% |
| Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
| Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
| Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
| Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
| Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
| Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
| Dec 31, 2011 | 18.31B | 2.19B | 13.59% |
| Dec 31, 2010 | 16.12B | 2.22B | 15.99% |
| Dec 31, 2009 | 13.90B | 2.81B | 25.39% |
| Dec 31, 2008 | 11.09B | 1.68B | 17.83% |
| Dec 31, 2007 | 9.41B | 1.00B | 11.89% |
| Dec 31, 2006 | 8.41B | 3.16B | 60.15% |
| Dec 31, 2005 | 5.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Danel (Adir Yeoshua) | 2.98B |
| Amal Holdings A.D. | 2.18B |
| Novolog (Pharm-Up 1966) | 1.81B |
| Ilex Medical | 885.35M |
| Kamada | 571.54M |
| SofWave Medical | 310.85M |
| InterCure | 270.20M |
| BrainsWay | 180.82M |
Teva Pharmaceutical Industries News
- 3 hours ago - Teva unit bids to acquire neuroscience product from BioXcel Therapeutics - TheFly
- 3 hours ago - Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy - GlobeNewsWire
- 3 hours ago - BioXcel Therapeutics enters asset sale agreement with Teva - TheFly
- 8 days ago - Aurinia settles patent litigation with Teva - TheFly
- 8 days ago - Aurinia Settles Patent Litigation with Teva - Business Wire
- 8 days ago - TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer - TipRanks
- 9 days ago - Teva announces FDA acceptance of ecopipam NDA - TheFly
- 9 days ago - U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome - GlobeNewsWire